Gregory J. Withbroe
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gregory J. Withbroe.
Bioorganic & Medicinal Chemistry | 2003
Banavara L. Mylari; Gregory J. Withbroe; David A. Beebe; Nathaniel S. Brackett; Edward L. Conn; James B. Coutcher; Peter J. Oates; William James Zembrowski
Two new templates, (R) 2-hydroxyethyl-pyridine and (R) 2-hydroxyethyl-triazine, were used to design novel sorbitol dehydrogenase inhibitors (SDIs). The design concept included spawning of these templates to function as effective ligands to the catalytic zinc within the enzyme through incorporation of optimally substituted piperazino-triazine side chains so as to accommodate the active site in the enzyme for efficient binding. This strategy resulted in orally active SDIs, which penetrate key tissues, for example, sciatic nerve of chronically diabetic rats. The latter template led to the design of the title inhibitor, 33, which normalized the elevated sciatic nerve fructose by 96% at an oral dose of 10mg/kg.
Synthetic Communications | 2008
Frank Robert Busch; Paul E. Concannon; Robert Eugene Handfield; Jason D. McKinley; Megan E. McMahon; Robert A. Singer; Timothy J. N. Watson; Gregory J. Withbroe; Mariano Stivanello; Lucia Leoni; Chiara Bezze
Abstract Described here is the synthesis of (1‐(aminomethyl)‐2,3‐dihydro‐1H‐inden‐3‐yl)methanol 1, the previously unidentified impurity found in the synthesis of 2,1 providing a confirmation of the structure. Fabbrica Italiano Sintetici (FIS), working in conjunction with Pfizer Groton, reported an unidentified impurity, referred to as the “main band impurity”, in 2 at levels of 0.4 to 0.8%. The structure was postulated to be 1, the open‐ring product of the lithium aluminum hydride (LAH) reduction of 3 to 2. Although the cis isomer of 1 was previously reported in the literature,2 a much shorter racemic synthesis was developed using intermediates employed for the production of Varenicline®. Several reducing agents were screened for the synthesis of 1, with LiAlH4 followed by basic workup conditions giving optimal results. High performance liquid chromatography (HPLC) analysis ultimately confirmed the structure of 1 as the main band impurity generated during the synthesis of 2.
Organic Process Research & Development | 2008
Gregory J. Withbroe; Robert A. Singer; Janice E. Sieser
Journal of Medicinal Chemistry | 2005
Banavara L. Mylari; Sandra J. Armento; David A. Beebe; Edward L. Conn; James B. Coutcher; Michael S. Dina; Melissa T. O'gorman; Michael C. Linhares; William H. Martin; Peter J. Oates; David A. Tess; Gregory J. Withbroe; William James Zembrowski
Journal of Medicinal Chemistry | 2003
Banavara L. Mylari; Sandra J. Armento; David A. Beebe; Edward L. Conn; James B. Coutcher; Michael S. Dina; Melissa T. O'gorman; Michael C. Linhares; William H. Martin; Peter J. Oates; David A. Tess; Gregory J. Withbroe; William James Zembrowski
Journal of Medicinal Chemistry | 2002
Banavara L. Mylari; Peter J. Oates; William James Zembrowski; David A. Beebe; Edward L. Conn; James B. Coutcher; Melissa T. O'gorman; Michael C. Linhares; Gregory J. Withbroe
Organic Process Research & Development | 2014
Brian P. Chekal; Steven M. Guinness; Brett M. Lillie; Robert William Mclaughlin; Charles W. Palmer; Ronald J. Post; Janice E. Sieser; Robert A. Singer; Gregory W. Sluggett; Rajappa Vaidyanathan; Gregory J. Withbroe
Organic Process Research & Development | 2013
Gregory J. Withbroe; Chris Seadeek; Kevin P. Girard; Steven M. Guinness; Brian C. Vanderplas; Rajappa Vaidyanathan
Archive | 2006
Frank Robert Busch; Joel M. Hawkins; Lasson Georgios Mustakis; Terry Gene Sinay; Timothy J. N. Watson; Gregory J. Withbroe
Archive | 2007
Karen S. Bronk; Frank Robert Busch; Terry Gene Sinay; Gregory J. Withbroe